Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Coppola, Nicola ^a   Zampino, Rosa ^a   Sagnelli, Caterina ^a   Bellini, Giulia ^a   Marrone, Aldo ^a   Stanzione, Maria ^a   Capoluongo, Nicolina ^a   Boemio, Adriana ^a   Minichini, Carmine ^a   Adinolfi, Luigi Elio ^a   Maione, Sabatino ^a   Del Giudice, Emanuele Miraglia ^a   Sagnelli, Evangelista ^a   Rossi, Francesca ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CANNABINOID 2 RECEPTOR; GENOMIC DNA; GLUTAMINE; VIRUS RNA; ALANINE AMINOTRANSFERASE; CNR2 PROTEIN, HUMAN;

ADULT; AMINO ACID SUBSTITUTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CNR2 GENE; CODON; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; VIROLOGY; VIRUS LOAD; AGED; BLOOD; CHRONIC HEPATITIS C; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALANINE TRANSAMINASE; FEMALE; GENETIC ASSOCIATION STUDIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB2;

EID: 84903306630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099450     Document Type: Article

References (54)

1. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462. (Pubitemid 44394908)
2. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, et al. (2011) Endocannabinoids in liver disease. Hepatology 53: 346-55.
3. Cabral GA, Griffin-Thomas (2008) Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets 8: 159-72.
4. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, et al. (2011) Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54: 1217-26.
5. Basu PP, Aloysius MM, Shah NJ, Brown RS (2014) Review article: the endocannabinoid system in liver disease, a potential therapeutic target. Aliment Pharmacol Ther 39: 790-801.
6. Carrasquer A, Nebane NM, Williams WM, Song ZH (2010) Functional consequences of non synonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor. Pharmacogenet Genomics 20: 157-166.
7. Sipe JC, Arbour N, Gerber A, Beutler E (2005) Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol 78: 231-8. (Pubitemid 40979962)
8. Wong JB, McQuillan GM, McHutchison JG, Poynard T (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90: 1562-1569.
9. Gentile I, Coppola N, Pasquale G, Liuzzi R, D'Armiento M, et al. (2013) A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic hepatitis C. Hepat Mon 8; 13: e8352.
10. Prati D, Gasbarrini A, Mazzotta F, for AISF, SIMAST and SIMIT (2010) Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 42: 81-91.
11. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, et al. (2002)Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 37: 117-23. (Pubitemid 34713063)
12. Pasquale G, Sagnelli E, Coppola N, Scarano F, Scolastico C, et al. (2003) Is the liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels? Eur J Gastroenterol Hepatol 15: 831-833. (Pubitemid 36870664)
13. Persico M, Persico E, Suozzo R, Conte S, De Seta M, et al. (2000) Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118: 760-4. (Pubitemid 30171625)
14. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, et al. (2013) Presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 11: 1174-1180. e11.
15. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, et al. (2009) HBV Superinfection in HCV Chronic Carriers: A Disease That Is Frequently Severe but Associated with the Eradication of HCV. Hepatology 49: 1090-7.
16. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, et al. (2001) Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34: 283-287. (Pubitemid 32702341)
17. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, et al. (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358-64. (Pubitemid 32496971)
18. Ishida JH, Jin C, Bacchetti P, Tan V, Peters M, et al. (2008) Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 6: 69-75. (Pubitemid 350309529)
19. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
20. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
21. Coppola N, Zampino R, Bellini G, Macera M, Marrone A, et al. (2014) Cannabinoid receptor 2-63 QQ variant is associated with severe necroinflammation in chronic hepatitis C. Clin Gastroenetrol Hep 12: 334-340.
22. Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, et al. (2014) Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV-HCV dual infection. Eur J Clin Microbiol Infect Dis 33: 559-67.
23. Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, et al. (2013) Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 20: 517-523.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
25. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-21. (Pubitemid 40770284)
26. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, et al. (2006) Hepatitis C virus superinfection in hepatitis B virus chronic carriers: A reciprocal viral interaction and a variable clinical course J Clin Virol 35: 317-20. (Pubitemid 43188980)
27. Romeo R, Colombo M, Rumi M, Soffredini R, Del Ninno E, et al. (1996) Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 3: 183-90. (Pubitemid 126733933)
28. McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW (1996) Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 23: 676-87. (Pubitemid 26111977)
29. García F, Roldàn C, Hernàndez-Quero J, Bernal MC, Martínez MA, et al. (1996) Relationship between viral genotype and viral load in patients with chronic hepatitis C. Eur J Clin Microbiol Infect Dis 15: 884-7. (Pubitemid 26421626)
30. Shindo M, Arai K, Sokawa Y, Okuno T (1995) The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 22: 418-25.
31. Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H (2012) Clinical Features of Hepatitis C Virus Carriers With Persistently Normal Alanine Aminotransferase Levels. Hepat Mon 12: 77-84.
32. Rossi F, Mancusi S, Bellini G, Roberti D, Punzo F, et al. (2011) CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura. Haematologica 96: 1883-5.
33. Rossi F, Bellini G, Tolone C, Luongo L, Mancusi S, et al. (2012) The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res 66: 88-94.
34. Shrivastava S, Mukherjee A, Ray R, Ray RB (2013) Hepatitis C Virus Induces Interleukin-1b (IL-1b)/IL-18 in Circulatory and Resident Liver Macrophages. J Virol 87: 12284-90.
35. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE (2013) Kupffer cells in the liver. Compr Physiol 3: 785-97.
36. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, et al. (2014) M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and non-alcoholic fatty liver disease. Hepatology 59(1): 130-42.
37. Luongo L, Guida F, Boccella S, Bellini G, Gatta L, et al. (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS NeurolDisord Drug Targets 12: 45-54.
38. Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, et al. (2003) Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 170: 1249-56. (Pubitemid 36139490)
39. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, et al. (2004) Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 113: 963-72. (Pubitemid 38544117)
40. Blackburn SD, Wherry EJ (2007) IL-10, T cell exhaustion and viral persistence. Trends Microbiol 15: 143-6. (Pubitemid 46528253)
41. Kondo Y, Sung VM, Machida K, Liu M, Lai M (2007) Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology 361: 161-73. (Pubitemid 46551226)
42. Machida K, Kondo Y, Huang JY, Chen YC, Cheng KT, et al. (2008) Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol 82: 6711-20. (Pubitemid 351875146)
43. Blackburn SD, Crawford A, Shin H, Polley A, Freeman GJ, et al. (2010) Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol 84: 2078-89.
44. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, et al. (1997) The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158: 1473-81. (Pubitemid 127469976)
45. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY (1998) Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28: 225-30. (Pubitemid 28300005)
46. Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, et al. (2000) Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 32: 597-603.
47. Itose I, Kanto T, Kakita N, Takebe S, Inoue M, et al. (2009) Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat 16: 844-52.
48. Rossi F, Bellini G, Nobili B, Maione S, Perrone L, et al. (2011) Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: an alternative way to highlight the CB2 hepatoprotective properties. Hepatology 54: 1102-1103.
49. Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, et al. (2010) Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52: 1046-1059.
50. Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, et al. (2010) Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappa B. Glia 58: 135-47.
51. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, et al. (2012) Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(2/2) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258: 256-67.
52. Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, et al. (2013) Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol 8: 1265-76.
53. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, et al. (2003) Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38: 859-68. (Pubitemid 37221669)
54. Cable JC, Tan GD, Alexander SP, O'Sullivan SE (2011) The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans. Lipids Health Dis 10: 129.